Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AVINZA vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AVINZA (morphine sulfate) is a full opioid agonist that binds to mu-opioid receptors in the CNS, producing analgesia by altering pain perception and emotional response to pain.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Management of opioid-experienced patients with moderate to severe chronic pain requiring daily, around-the-clock opioid therapy for an extended period of time
Mild to moderate pain,Fever
Oral, 30 mg once daily (q24h) for opioid-naïve patients; titrate based on response. Maximum daily dose 160 mg. Administer with food to minimize peak effects.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life of morphine is approximately 1.5-2 hours; however, due to the extended-release formulation, the effective half-life is prolonged to about 9-11 hours, allowing once-daily dosing.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily hepatic via glucuronidation by UGT2B7 to morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G); minor CYP2C9 involvement.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily renal (approximately 90% as morphine metabolites, mainly morphine-3-glucuronide and morphine-6-glucuronide); biliary/fecal excretion accounts for less than 10%.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Approximately 30-40% bound to plasma proteins, primarily albumin.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Approximately 3-4 L/kg, indicating extensive tissue distribution.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral bioavailability of morphine is variable (approximately 20-40%) due to extensive first-pass metabolism; the extended-release formulation provides consistent absorption over 24 hours.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
For GFR 30-59 m L/min: initiate at 50% of usual dose and titrate carefully; GFR <30 m L/min: initiate at 25% of usual dose; avoid in severe renal impairment (GFR <15 m L/min).
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class A: initiate at 50% of usual dose; Class B: initiate at 25% of usual dose; Class C: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not recommended in pediatric patients <18 years; safety and efficacy not established. For adolescent patients (≥18 kg), off-label use: 0.1-0.2 mg/kg/dose q4-6h PRN; extended-release formulations not intended for children.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
For patients ≥65 years: initiate at 50% of adult dose (15 mg once daily) and titrate cautiously due to increased sensitivity, reduced renal/hepatic function, and higher risk of respiratory depression. Consider lower starting doses and extended intervals.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; AND RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Risk of life-threatening respiratory depression; addiction, abuse, and misuse; neonatal opioid withdrawal syndrome; interactions with CNS depressants; severe hypotension; gastrointestinal obstruction; seizure risk; impaired mental or physical abilities.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction; paralytic ileus; hypersensitivity to morphine sulfate.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid alcohol and alcohol-containing products (e.g., some mouthwashes, extracts) due to risk of dose dumping. Grapefruit juice may increase morphine bioavailability; limit intake. High-fat meals may delay absorption but not significantly alter overall exposure.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Prolonged use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Avoid chronic use near term.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Morphine is excreted into breast milk; M/P ratio approximately 1:1. Infant exposure is dose-dependent; monitor for sedation, respiratory depression, and withdrawal. Use with caution; avoid in breastfeeding women with known infant risk factors.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Increased clearance and volume of distribution during late pregnancy may require dose adjustments. Use lowest effective dose for shortest duration. Avoid extended-release formulations near term; consider immediate-release morphine for acute pain management.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
AVINZA is an extended-release morphine formulation using the SODAS (Spheroidal Oral Drug Absorption System) technology, consisting of immediate-release and sustained-release beads. It must be taken whole; crushing or chewing can lead to rapid release and fatal overdose. Do not use in opioid-naïve patients; initiate with lower strengths if converting from other opioids. Monitor for signs of serotonin syndrome when co-administered with serotonergic drugs. Avoid alcohol consumption; ethanol can cause dose dumping.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take this medication exactly as prescribed; do not crush, chew, or break the capsules.,Swallow the capsules whole; if you have trouble swallowing, you may open the capsules and sprinkle the beads onto a small amount of soft food (e.g., applesauce) and swallow immediately without chewing.,Do not consume alcohol or any products containing alcohol while taking AVINZA, as it can lead to a dangerous increase in morphine levels.,This medication has a high risk of addiction, abuse, and misuse; store it safely and dispose of unused tablets properly.,Common side effects include constipation, nausea, drowsiness, and dizziness; report severe or persistent symptoms to your doctor.,Do not stop suddenly; withdrawal symptoms may occur; your doctor will guide you on tapering the dose.,Avoid driving or operating heavy machinery until you know how this medication affects you.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AVINZA vs ACEPHEN, answered by our medical review team.
AVINZA is a Opioid Analgesic that works by AVINZA (morphine sulfate) is a full opioid agonist that binds to mu-opioid receptors in the CNS, producing analgesia by altering pain perception and emotional response to pain.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AVINZA and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AVINZA is: Oral, 30 mg once daily (q24h) for opioid-naïve patients; titrate based on response. Maximum daily dose 160 mg. Administer with food to minimize peak effects.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AVINZA and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AVINZA is classified as Category C. First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Prolonged use may cause neonatal o. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.